Researchers have thought for years that a protein product of the APOE gene protein, called APOE4, increases Alzheimer’s risk by binding to another protein, called beta- amyloid, that then increases the likelihood of “amyloid plaque” formation in the brain, one of the hallmarks of this disease. APOE3 is another form of the APOE gene that is thought to reduce the risk of developing Alzheimer’s. BrightFocus-funded researcher, Philip Verghese, Ph.D., was the lead author on a project that suggests scientists may have to revise their ideas of how different forms of the APOE actually influences the risk of developing Alzheimer’s.
The new findings suggest that forms of APOE and beta-amyloid are actually unlikely to bind together in the fluids circulating the brain, based on research in mice. This means that scientists will need to rethink any therapeutic strategies that target the high risk form, called APOE4, to slow amyloid plaque accumulation as a treatment or preventive strategy for Alzheimer’s disease. Although targeting APOE is a promising approach, it will be crucial to fully understand how the harmful forms of APOE increase risk of the disease.
In fact, Verghese and colleagues suggest that the different forms of APOE essentially compete with beta-amyloid for the same binding spots on cells that normaly ingest, degrade and clear the beta-amyloid protein from the brain. APOE4 reduces the ability of the cells to ingest and degrade beta-amyloid. Projects are underway that will clarify exactly how APOE contributes to amyloid plaque formation, and that will hopefully lead to more precise and effective treatments for this degenerative brain disease.
- A BrightFocus Foundation research grant supports lead author, Philip Verghese, Ph.D.
- Co-author Carl Frieden, Ph.D., is currently funded for another Alzheimer’s disease project:
- Co-author Guojon Bu, Ph.D., is a past BrightFocus grantee for another Alzheimer’s Disease Research project:
Scientists’ picture of how a gene strongly linked to Alzheimer’s disease harms the brain may have to be revised, researchers at Washington University School of Medicine in St. Louis have found.
People with harmful forms of the APOE gene have up to 12 times the risk of developing Alzheimer’s disease compared with those who have other variations of the gene.
Many researchers believe that the memory loss and cognitive problems of Alzheimer’s result from the buildup over many years of brain amyloid plaques. The plaques are made mostly of a sticky substance called amyloid beta. For years, researchers have thought that the APOE gene increases Alzheimer’s risk by producing a protein that binds to amyloid beta. Scientists thought that this bond could make it easier for plaques to form.
But in a new study now available online in the Proceedings of the National Academy of Sciences, Washington University researchers show that APOE and amyloid beta don’t bind together in cerebrospinal fluid and in fluids present outside cells grown in dishes. This means they are unlikely to bind together in the fluids circulating in the brain. The cerebrospinal fluid was taken from people who were cognitively normal but have forms of APOE that increase the risk of Alzheimer’s.
“This is the first time we’ve looked at naturally produced APOE and amyloid beta to see if and how much they bind together, and we found that they have very little interaction in the fluids bathing the brain,” said David M. Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of neurology. “This suggests that we may need to rethink any therapeutic strategies that target APOE to slow amyloid plaque accumulation and Alzheimer’s.”
According to Holtzman, leading Alzheimer’s researchers recently agreed that targeting APOE is a promising approach both for gaining a better understanding of and improving treatments for Alzheimer’s. But to do that, scientists must first fully understand how the harmful forms of APOE increase risk of the disease.
“APOE is a major player in Alzheimer’s, there’s no question about that,” said Philip Verghese, PhD, a postdoctoral research associate. “We did some additional studies in mice and cell cultures that suggested the APOE protein may be blocking a pathway that normally helps degrade amyloid beta.”
APOE is involved in the metabolism of fats, cholesterol and vitamins throughout the body. Scientists have identified three different forms of the gene that each make a slightly different version of the protein.
One version, APOE 2, produces a protein that significantly reduces Alzheimer’s risk. Another, APOE 4, increases risk. Each person has two copies of the gene, and if both copies are APOE 4, the chance of developing Alzheimer’s rises dramatically.
“About 60 percent of the patients we see in the Alzheimer’s clinics have at least one copy of APOE 4,” Holtzman said. “In contrast, only about 25 percent of cognitively normal 70-year-olds have a copy of APOE 4.”
Verghese tested cerebrospinal fluid samples from people who had either two copies of APOE 4 or two copies of APOE 3, another form of the gene that is not associated with increased Alzheimer’s risk.
“We also found that APOE 2, the protective form of the protein, doesn’t bind to amyloid beta in body fluids,” Verghese said.
In follow-up studies, Verghese showed that APOE and amyloid beta “compete” to bind to a receptor on support cells in the brain known as astrocytes.
“Studies by other researchers have shown that astrocytes can degrade amyloid beta,” Verghese said. “The receptor we identified may be important for getting amyloid beta into the astrocyte so it can be broken down. It’s possible that when the harmful forms of APOE bind to the receptor, this reduces the opportunities for amyloid to be degraded.”
The researchers are planning follow-up studies of the effects of APOE-blocking treatments in mice.
This work was supported by the BrightFocus Foundation (formerly American Health Assistance Foundation) and the National Institutes of Health (Grants AG034004 , AG13956, NS074969, and AG027924).
Adapted from Washington University School of Medicine
View all news updates for Alzheimer's disease
Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.